19.86  0.74 (3.87%)		01-27 11:38
Open: 19.12 High: 20 Volume: 96,196		Pre. Close: 19.12 Low: 18.7628 Market Cap: 308(M)

Short term
Mid term
Targets	6-month :	23.94	1-year :	26.85
Resists	First :	20.49	Second :	22.98
Pivot price	18.3
Supports	First :	16.46	Second :	13.7
MAs	MA(5) :	18.86	MA(20) :	18.79
	MA(100) :	22.51	MA(250) :	19.56
MACD	MACD :	-0.6	Signal :	-0.8
%K %D	K(14,3) :	67	D(3) :	50.4
RSI	RSI(14): 52
52-week	High :	37.26	Low :	6.87

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ NGNE ] has closed below upper band by 5.5%. Bollinger Bands are 62% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	19.75 - 19.85	19.85 - 19.94
Low:	17.95 - 18.05	18.05 - 18.15
Close:	18.95 - 19.11	19.11 - 19.27

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.

Mon, 26 Jan 2026
LifeSci Capital Initiates Coverage of Neurogene (NGNE) with Outperform Recommendation - Nasdaq

Mon, 12 Jan 2026
Rett syndrome families watch a new gene therapy reach key 2026 tests - Stock Titan

Mon, 05 Jan 2026
Genetic medicines firm Neurogene opens its health conference talk online - Stock Titan

Mon, 24 Nov 2025
Neurogene: From Speculation To Execution With NGN-401 (NASDAQ:NGNE) - Seeking Alpha

Thu, 13 Nov 2025
Neurogene Inc. (NGNE) Stock Analysis: Exploring an 85.81% Potential Upside in Biotechnology - directorstalkinterviews.com

Wed, 12 Nov 2025
Neurogene Announces Positive Interim Data for NGN-401 - TipRanks

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	15 (M)
Shares Float	5 (M)
Held by Insiders	8.5 (%)
Held by Institutions	104.8 (%)
Shares Short	3,500 (K)
Shares Short P.Month	3,290 (K)

EPS	-4.1
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	17.96
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-27 %
Return on Equity (ttm)	-42.3 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	-4.51
Sales Per Share	0
EBITDA (p.s.)	-6.09
Qtrly Earnings Growth	0 %
Operating Cash Flow	-77 (M)
Levered Free Cash Flow	-47 (M)

PE Ratio	-4.79
PEG Ratio	0
Price to Book value	1.09
Price to Sales	0
Price to Cash Flow	-3.94

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.